Legorreta Pablo G. 4

What Happened
Pablo G. Legorreta, a reported 10% owner of ProKidney Corp. (PROK), was granted 135,000 derivative shares (reported as acquired at $0.00) on 2026-05-28. The award is reported as a derivative security (an option/award under the issuer’s non-employee director compensation policy) and the filing lists the acquisition value as $0.00.

Key Details

• Transaction date: 2026-05-28; Form 4 filed 2026-05-29 (appears timely).
• Amount granted: 135,000 derivative shares; acquisition price reported as $0.00.
• Shares owned after the transaction: Not specified in the provided summary of the filing.
• Footnotes: (F1) Grant made under the issuer’s non-employee director compensation policy. (F2) Options vest in full on the earlier of the one-year anniversary of grant or the Company’s next annual general shareholder meeting.
• Filing type: Award/Grant (code A, derivative); no sale, open-market purchase, or immediate exercise reported.

Context
This was a compensation-related award to a significant shareholder who also receives non-employee director compensation; it is not an open-market purchase or sale. As a derivative award, vesting conditions (noted above) determine when the recipient gains full rights; the filing does not indicate any immediate sale of underlying shares. Being a 10% owner signifies a substantial insider holding and triggers Section 16 reporting, but the grant itself should be read as compensation, not an explicit bullish or bearish market signal.